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Abstract
Background: The investigation of the environmental contribution for developmental neurotoxicity is very critical.
Many environmental chemical exposures are now thought to contribute to the development of neurological
disorders, especially in children. Results from animal studies may guide investigations of human populations
towards identifying either environmental toxicants that cause or drugs that protect from neurotoxicity and may
help in treatment of neurodevelopmental disorders.
Objective: To study both the protective and therapeutic effects of N-acetyl cysteine on brain intoxication induced
by propionic acid (PPA) in rats.
Methods: Twenty-eight young male Western Albino rats were enrolled in the present study. They were grouped
into four equal groups, each of 7 animals. Group 1: control group, orally received only phosphate buffered saline;
Group 2: PPA-treated group, received a neurotoxic dose of of PPA of 250 mg/kg body weight/day for 3 days; Group
3: protective group, received a dose of 50 mg/kg body weight/day N-acetyl-cysteine for one week followed by a
similar dose of PPA for 3 days; and Group 4: therapeutic group, treated with the same dose of N-acetyl cysteine
after being treated with the toxic dose of PPA. Serotonin, interferon gamma (IFN-γ), and glutathione-s-transferase
activity, together with Comet DNA were assayed in the brain tissue of rats in all different groups.
Results: The obtained data showed that PPA caused multiple signs of brain toxicity as measured by depletion of
serotonin (5HT), increase in IFN-γ and inhibition of glutathione-s-transferase activity as three biomarkers of brain
dysfunction. Additionally Comet DNA assay showed remarkably higher tail length, tail DNA % damage and tail
moment. N-acetyl-cysteine was effective in counteracting the neurotoxic effects of PPA.
Conclusions: The low dose and the short duration of N-acetyl-cysteine treatment tested in the present study
showed much more protective rather than therapeutic effects on PPA-induced neurotoxicity in rats, as there was a
remarkable amelioration in the impaired biochemical parameters representing neurochemical, inflammatory,
detoxification and DNA damage processes.
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Introduction
The impact of environmental chemicals on children's
neurodevelopment is sometimes treated as an unimportant
issue because of the insignificant clinical impairments.
Such a judgment reflects a failure to distinguish between
individual and population risk. The population impact
of a risk factor depends on both its size of effect and
distribution (or incidence/prevalence) [1]. The particular
vulnerability of the developing nervous system for
low-level exposure to chemicals is well established. It
has been argued that a large number of environmental
chemicals cause some degree of developmental neuro-
toxicity. However, for only a few of these, human evi-
dence was able to suggest that exposure to chemicals
could be contributing to neurodevelopmental disorders
like autism, attention-deficit disorder, mental retardation
or cerebral palsy [2].
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Propionic acid (PPA) is an intermediate in cellular
fatty acid metabolism. It is found in high levels in the
gut, along with a number of other short chain fatty
acids, such as acetate and butyrate, each of which is a
product of enteric bacteria [3]. PPA may play a role in
the behavioural, neuropathological and biochemical
abnormalities observed in autism. It is capable of gaining
access to the brain and inducing different adverse effects
on the central nervous system [4]. Recent work reported
the potency of PPA in altering dopamine, serotonin, and
glutamate as neurotransmitter systems involved in the
aetiology of neurodevelopmental disorders [5-7], partly via
stimulating intracellular calcium release [8,9]. Additionally,
alterations in the serotonin and dopamine systems have
been implicated in abnormal social and motor behaviours
[5,6,10], similar to the symptoms observed in both autistic
patients and PPA animal models of MacFabe et al. [11].
PPA is also known to potentiate glutamatergic transmission
[12], inhibit GABAergic transmission and potentiate the
production of enkephalin [8,13] supportive of a potential
mechanism for the enhanced excitation/reduced inhibition
theory of autism [14]. Moreover, the inflammatory action of
PPA was reported through the induction of interleukin-6
(IL-6), tumour necrosis factor-α (TNF-α) and interferon-γ
(IFN-γ) as proinflammatory cytokines [7,11]. Recently,
depletion of glutathione (GSH), lower activity of gluta-
thione peroxidase and elevation of lipid peroxides are
among the most persistent neurotoxic effects of orally
administered PPA [3]. GSH has a critical role in both
antioxidant defence and detoxification of xenobiotics
for a broad range of environmental chemicals [15,16],
including those implicated in autism spectrum disorders.
Impairments in GSH-associated pathways suggest reduced
cellular defence and are therefore considered as markers
of increased oxidative stress [15,17].
Oxygen is both essential and toxic to all forms of aerobic
life and the chemical versatility and reactivity of thiols play
a key role in both aspects. Cysteine thiol groups have key
catalytic functions in enzymes and are readily damaged by
reactive oxygen species (ROS). Low-molecular-weight
thiols provide protective buffers against the hazards of
ROS toxicity. GSH is the small protective thiol in nearly all
eukaryotes, but in prokaryotes the situation is far more
complex [18]. Depletion of intracellular GSH appears to
be critical for subsequent alterations in protein thiols
and calcium homeostasis [19]. GSH depletion and the
subsequent low stores of protein thiols result in both
calcium release from intracellular stores and inhibition
of calcium extrusion, producing a marked increase in
cytosolic calcium concentration, which triggers cytotoxicity
[19]. The brains of patients with autism spectrum disorders
and animal models exhibited a reduction of GSH [10]. It
was postulated to be of significance in the pathogenesis of
this disease via oxidative damage [20,21]. Cysteine, the
rate-limiting amino acid for GSH synthesis, was signifi-
cantly decreased in autistics relative to the control children
suggesting that GSH synthesis was insufficient to maintain
redox homeostasis [16]. GSH depletion occurred without a
change in GSSG (oxidised form of GSH), suggesting efflux
of GSH out of the glia, perhaps with additional increase
in the conversion of GSH to GSSG in response to the
increased hydrogen peroxide formation [22]. At this point
it is unclear whether free radical involvement in autism is a
primary or secondary event in brain cell death, or whether
or not it occurs early or late in the disease process.
Based on the fact that an impaired cysteine uptake from
the plasma has been proposed secondary to a decrease in
plasma GSH, this work was undertaken to investigate the
protective and therapeutic effects of oral supplementation
of N-acetyl-cysteine (NAC) to ameliorate the persistent
biochemical autistic features induced in PPA-treated rats.
Materials and methods
Animals
This is an interventional experimental animal study
performed on twenty-eight male western albino rats (45 to
60 g, approximately 21 days old). Rats were obtained from
the Pharmacy College animal house at King Saud University.
They were kept under standard conditions of temperature,
12-h dark/light cycle and were given free access to tap water
and standard laboratory chow. After one week of acclima-
tion, the rats were divided into four groups (seven rats in
each group), namely the control group in which animals
were fed normal diet during the experimental period; the
PPA treated rats that received 250 mg/kg body weight/day
for 3 days, in order to induce autistic features; the protective
group which received 50 mg/kg/day of NAC for one
week followed by oral PPA (250 mg/kg body weight/day
for 3 days); and the therapeutic group that received
NAC for one week after PPA oral dose for three days.
Tissue preparation
At the end of the feeding trials, the rats were anesthetized
with carbon dioxide and decapitated. The brain was
removed from the skull and dissected into small pieces
and homogenized in 10 times w/v bi-distilled water
and kept at −80°C until further use for different biochem-
ical analyses. A small piece of brain was kept separately for
Comet DNA assay.
Ethics approval and consent
This work was approved by the Ethical committee of
Science College at King Saud University (Approval no
8/25/220358).
Assay of serotonin
Serotonin was measured using an ELISA kit from
Immuno-Biological Laboratories (IBL, Hamburg, Germany)
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[23]. Brain homogenate preparation (derivatization of
serotonin to N-acyl-serotonin) was part of the sample
dilution which was achieved by the incubation of the
respective sample with the acylating reagent. The assay
procedure followed the competitive ELISA protocols
whereby competition takes place between biotinylated
and non-biotinylated antigens for a fixed number of
antibody binding sites. The amount of biotinylated antigens
bound to the antibodies was inversely proportional to the
N-acyl-serotonin concentration of the sample.
Assay of IFN-γ
IFN-γ was measured using an ELISA kit, a product of
Thermo Scientific (Rockford, IL, USA) [24] according
to the manufacturer’s instructions. This assay employs
a quantitative sandwich enzyme immunoassay technique
that measures IFN-γ in less than five hours. The minimum
level of rat IFN-γ detected by this product was less than
2 pg/mL.
Determination of glutathione-S-transferase activity (GST)
GST activity was assessed using (Biovision, USA) assay kit,
based upon the GST-catalysed reaction between GSH,
GST substrate, and CDNB (1-chloro-2,4-dinitrobenzene).
The GST-catalysed formation of GS-DNB produces a
dinitrophenyl thioether which can be spectrophotometric-
ally detected at 340 nm.
Comet DNA assay
Single cell gel electrophoresis or Comet assay is one of
the simple, sensitive and rapid methods for the detection
and quantification of DNA damage [25]. Slides were pre-
pared in duplicate per group and the test was performed
for at least 3 different brain samples from each group. Cell
suspension, about 4 × 106 cells were mixed with 80 μL of
0.7% low-melting agarose in phosphate-buffered saline
(PBS) at 37°C in a microtube, and then spread over a
window microscopic slide. The slides were pre-coated with
150 μL of 0.5% normal-melting agarose in PBS, and were
Table 1 One-way ANOVA test between serotonin (ng/100 mg), IFN-γ (pg/100 mg) and GST (μmol/min/100 mg) in
control, PPA-intoxicated and NAC protected and treated rats
Parameters Groups Min Max Mean ± SD P value
Serotonin (ng/100 mg) Control 3.41 4.80 4.12 ± 0.51 0.001
PPA 2.32 3.03 2.76 ± 0.29 a
NAC protective 3.12 3.94 3.53 ± 0.27 a
NAC therapeutic 2.58 3.25 2.94 ± 0.27 a
IFN-γ (pg/100 mg) Control 88.27 115.64 99.91 ± 8.84 0.001
PPA 177.34 194.59 184.72 ± 6.24 a
NAC protective 149.07 163.59 156.99 ± 5.23 a
NAC therapeutic 160.57 171.66 167.60 ± 4.01 a
GST (μmol/min/100 mg) Control 0.78 0.95 0.85 ± 0.06 0.001
PPA 0.44 0.55 0.50 ± 0.04 a
NAC protective 0.62 0.77 0.69 ± 0.05 a
NAC therapeutic 0.59 0.70 0.65 ± 0.04 a
Significant levels between the three groups are illustrated as superscript letters when P <0.05.
Figure 1 Percentage change of serotonin, IFN-γ and GST in PPA-intoxicated, NAC protected and treated groups, compared to control.
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specially designed for this assay. Then, slides were placed
immediately in cold lysis buffer, 2.5 M sodium chloride
NaCl, 100 mM EDTA sodium salt Na2EDTA, 10 mM Tris
(pH 10), and 1% Triton X-100, at 4°C for a minimal of
1 hr. After lysis, the slides were drained and placed in a
horizontal gel electrophoresis tank surrounded by ice, and
filled with fresh cold electrophoresis buffer (300 mM so-
dium hydroxide NaOH, 1 mM NaEDTA, pH 13). To allow
DNA unwinding, the slides were kept in the high pH buffer
for 20 min. After that, electrophoresis was carried out for
20 min at 25 V and 300 mA. The slides were then drained
and flooded slowly with 3 changes of neutralization buffer
(0.4 M Tris, pH 7.5) for 5 min each, and then stained with
30 mL of ethidium bromide (20 mg/L), and covered with
cover slips. All those steps were performed under dimmed
light in order to prevent additional DNA damage caused by
visible light. A total of 50 randomly selected cells per slide
were analysed. Imaging was done using a fluorescence
microscope (Zeiss Axiovert L410 Inc., Jena, Germany),
attached to a digital camera (Olympus Inc., Tokyo, Japan),
and equipped with 549 nm excitation filter, 590 nm barrier
filter, and a 100-W mercury lamp. The percentage of
DNA in the comet tail "DNA damage" was automatically
calculated [25].
Comets were randomly captured at a constant depth of
the gel, avoiding the edges of the gel, occasional dead cells,
and superimposed comets. DNA damage was measured as
tail length (TL = distance of DNA migration from the
centre of the body of the nuclear core), and tail intensity
DNA (TI =% of genomic DNA that migrated during the
electrophoresis from the nuclear core to the tail). By
presenting all three parameters together, more information
could be obtained on the extent of DNA damage.
Statistical analysis
The data were analysed using the statistical package for
the social sciences (SPSS, Chicago, IL, USA). The results
were expressed as mean ± standard error of the mean
(SEM). All statistical comparisons between the control
and PPA-treated rat groups were performed using the
one-way analysis of variance (ANOVA) test complemented
with the Dunnett’s test for multiple comparisons.
Significance was assigned at the level of P <0.05. Receiver
operating characteristics (ROC) curve analysis was
performed. Area under the curve (AUC), cut-off values,
and degree of specificity and sensitivity were calculated.
Pearson correlations were calculated.
Results and discussion
Typically, an animal model is unlikely to replicate a
human disease [10]. The utility of such models relates to
the various types of validity that can be shown to exist
for specific models. An emerging hypothesis in autism is
Table 2 One-way ANOVA test between tail length (μm),
tail DNA % and tail moments (units) in control,
PPA-intoxicated and NAC-protected and treated rats
Parameters Groups Min Max Mean ± SD P value
Tail length
(μm)
Control 102.18 253.79 1.25 ± 0.16 0.001
PPA 112.06 372.45 4.96 ± 0.28 a
NAC protective 102.18 288.41 3.22 ± 0.23 a
NAC therapeutic 29.66 125.25 4.07 ± 0.14 a
Tail DNA % Control 48.99 95.00 1.40 ± 0.17 0.001
PPA 22.00 62.99 4.85 ± 0.27 a
NAC protective 18.20 58.80 3.18 ± 0.08 a
NAC therapeutic 9.70 26.60 4.12 ± 0.15 a
Tail moments
(units)
Control 34.48 37.06 1.76 ± 0.37 0.001
PPA 23.27 31.03 24.07 ± 1.87 a
NAC protective 32.32 36.20 10.23 ± 0.47 a
NAC therapeutic 20.68 28.01 16.80 ± 1.16 a
Significant levels between the three groups are illustrated as superscript
letters when P <0.05.
Figure 2 Percentage change of tail length, tail DNA% and tail moment in PPA-intoxicated, NAC-protected and treated groups
compared to control.
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the disequilibrium between oxidants and antioxidants in
the body which leads to the accumulation of ROS. Ori-
ginally ROS are removed by GSH, superoxide dismutase,
catalase, and glutathione peroxidase. Accumulation of
ROS can cause chemical and functional modification of
DNA, RNA, protein, lipid and carbohydrate moieties,
thereby resulting in cellular dysfunction. Our recent
study proved that PPA could induce significant redox
imbalance through GSH depletion, glutathione peroxidase
inactivation, and potentiation of lipid peroxidation as a
marker of oxidative stress [7].
Table 1 shows the potency of PPA in impairing the
detoxification mechanisms in treated rats with 41% lower
glutathione-s-transferase activity, a key family of enzymes
that detoxify pro-oxidative compounds by coupling them
to the body’s main antioxidant, GSH. This could support,
at least in part, that redox imbalance may cause the
neuronal insult and dysfunction seen in autistic patients
and animal models. These suggestions are consistent
with the study of James et al. [26], in which differences
in allele frequency and/or significant gene interaction
between individuals with autism and typically developing
control subjects were found with genes encoding
GSH-s-transferase. In the present study, NAC significantly
counteracted PPA-induced oxidative stress. Although, GSH-
s-transferase activities in NAC (protected and therapeutic)
groups are lower compared to control, both show much
higher activities compared to PPA-intoxicated group.
The anti-inflammatory effect of NAC reported in the
present study, demonstrated in Table 1 and Figure 1 as
significant reduction in the levels of IFN-γ, could be
supported through considering the previous reports about
the rationale use of NAC in Parkinson’s disease patients
which was based on the capacity of this compound to
reduce oxidative stress and inflammation. In fact, NAC
reduces cellular production of proinflammatory mediators
as IL-6 and stimulates the cellular GSH system [27].
Another anti-inflammatory effect of NAC was proved
to be through the inhibition of cyclooxygenase products
like prostaglandins [28] and down-regulation of TNF-α
production and their soluble receptors, as well as TGF-B
[29]. The protective effect of NAC reported in the present
study is in good agreement with the work of Lante et al.
[30], that pre-treatment with NAC prevented oxidative
stress and loss of long-term potentiation following exposure
to prenatal inflammation. Furthermore, lipopolysaccharide
treatment results in inhibited oligodendroglial cell de-
velopment and myelination that is attenuated by NAC
administration in rat mixed glial cultures [31].
ROS have been shown to modulate levels and activity
of noradrenaline (norepinephrine), serotonin, dopamine
and glutamate, the principal neurotransmitters involved
in the neurobiology of many brain diseases. These
observations introduce new potential targets for the
development of therapeutic interventions based on
antioxidant compounds such as NAC [32]. In addition to
the effects on oxidative balance, alterations in cysteine
levels have also been shown to modulate neurotransmitter
pathways, including glutamate and dopamine [33,34].
Cysteine assists in the regulation of neuronal intra- and
extracellular exchange of glutamate through the cysteine-
glutamate located on glial cells [35]. The dimer, cystine, is
taken up by astrocytes and exchanged for glutamate,
which is released into the extracellular space. This free
glutamate appears to stimulate inhibitory metabotropic
glutamate receptors on glutamatergic nerve terminals and









Figure 4 ROC curve of serotonin (ng/100 mg), IFN-γ (pg/100 mg)
and GST (μmol/min/100 mg) in PPA and NAC therapeutic groups.
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thereby reduce the synaptic release of glutamate [36].
Given that relation, the amount of cysteine in the system
as well as the feedback via GSH production by neurons
may directly regulate the amount of glutamate present in
the extracellular space. Furthermore, GSH itself has been
shown to potentiate brain N-methyl-d-aspartate receptor
response to glutamate in rats [37,38]. Changes in the
levels of neuronal GSH may not only alter available
glutamate levels, but also have direct consequences on
glutamatergic function. NAC as a source for cysteine
could be effective in ameliorating the impaired neuro-
transmission pathways induced by PPA neurotoxicity
[7]. In the present study, NAC was effective in inducing
serotonin levels, the 33% decrease of serotonin recorded
in PPA-treated rats was only reduced to a value of
14% and 29% decrease in NAC-protected and treated
rats, respectively. The recorded protective effect of
NAC reported in the present study could be supported
through the work of Lafleur et al. [39] in which NAC
augmentation of serotonin receptor inhibitor treatment
resulted in decreased symptoms in a single obsessive-
compulsive disorder case.
Table 2 and Figures 2 and 3 show the protective and
therapeutic effects of NAC against PPA neurotoxicity
which was demonstrated as a significant increase in the
tail length (297%), tail DNA % (247%), and a dramatic
increase in the tail moment (1271%). NAC given before
PPA was effective in reducing the increase in these
three parameters to values of 158%, 128% and 482%,
respectively. While NAC gave almost 60% reduction in
tail moment as marker of DNA double strand breaks, it
induced only 30% therapeutic potency against PPA-
induced effect. The recorded effect of NAC to protect
against PPA neurotoxicity could find a support in the
work of Reliene et al. [40] in which they recorded a pro-
tective effect of NAC against ionizing radiation-induced
DNA damage. Similar to our obtained findings, exposure
of human liver carcinoma (HepG2) cells to 30 mg/mL of
PbNO3 caused a substantial level of cell death associated
with a high degree of DNA damage, manifested by an
increase in percentage of DNA in the tail and olive
tail moment. Interestingly, co-treatment with a physio-
logic dose (500 mM) of NAC markedly lowered the






























Figure 6 ROC curve of tail length (μm), tail DNA % and tail
moments (units) in PPA, NAC protective and NAC
therapeutic groups.
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indicated that NAC protects macrophage cell line
(THP-1) against diesel exhaust particle chemicals [17].
Yang and his co-workers [41] also reported that NAC
lowers DNA damage produced by water-soluble cigarette
smoke in human lymphoid cells containing Epstein-Barr
virus episomes. In vitro studies suggest that the toxicity
and the increase in lipid peroxidation induced by lead in
cancer cell lines can be ameliorated by antioxidants such
as NAC [42].
Figures 4, 5 and 6 demonstrate the ROC analysis of the
measured parameters in PPA-intoxicated, NAC-protected
and NAC-therapeutically treated rats. It could be easily
noted that all the measured parameters show satisfactory
values of sensitivity and specificity. This could ascertain the
role of the measured parameters in testing the neurotoxic
effect of PPA and the effectiveness of NAC in ameliorating
the toxic effect of this short chain fatty acid.
The Pearson’s positive correlation seen in Figure 7
between serotonin and glutathione-s-transferase and the
negative correlation between IFN-γ and glutathione-s-
transferase could prove that the impairment of the detoxi-
fication mechanism represented by lower glutathione-s-
Figure 7 Pearson’s positive and negative correlations between the measured parameters.
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transferase activity with PPA is related to alteration of
brain neurochemistry represented by serotonin and induc-
tion of inflammatory responses represented by IFN-γ.
Taking into account the low dose and the short duration
of NAC treatment tested in the present study, NAC supple-
mentation could be suggested as a preventive strategy in
case of PPA neurotoxicity as an etiological factor recently
related to autism [7,43]. The effectiveness of NAC has also
been linked to its antioxidative properties. NAC increases
cysteine levels, thereby increasing the size of the glutathi-
one pool, compared to other antioxidants examined in
autism including omega-3 fatty acid and vitamin C which
only promote GSH recycling by facilitating the conversion
of GSSG into GSH without changing the size of the GSH
pool. The suggested use of NAC could find a support in
the recent randomized pilot investigation which proves the
potential usefulness of NAC for treating irritability and be-
havioural disturbance in children with autism [12]. Hence,
NAC treatment may be a promising therapeutic candidate
for chemoprevention against PPA toxicity.
Abbreviations
GSH: Glutathione; IFN-γ: Interferon-γ; IL-6: Interleukin-6; NAC: N-acetyl-
cysteine; PPA: Propionic acid; ROS: Reactive oxygen species; TNF-α: Tumour
necrosis factor-α.
Competing interests
The author(s) declare that they have no competing interests.
Authors’ contributions
AA: Suggested the topic and co-drafted the manuscript, RB: Performed the
practical work, AE: Design the work, drafted the manuscript and performed
the statistical analysis. All authors read and approved the final manuscript.
Acknowledgement
This research project was supported by a grant from the Research Center of
the Center for Female Scientific and Medical Colleges in King Saud
University.
Received: 22 November 2012 Accepted: 12 March 2013
Published: 27 March 2013
References
1. Bellinger DCA: Strategy for comparing the contributions of
environmental chemicals and other risk factors to neurodevelopment of
children. Environ Health Perspect 2012, 120(4):501–507.
2. Winneke G: Developmental aspects of environmental neurotoxicology:
lessons from lead and polychlorinated biphenyls. J Neurol Sci 2011,
308(1–2):9–15.
3. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT: Short
chain fatty acids in human large intestine, portal, hepatic and venous
blood. Gut 1987, 28:1221–1227.
4. Karuri AR, Dobrowsky E, Tannock IF: Selective cellular acidification and
toxicity of weak organic acids in an acidic microenvironment. Br J Cancer
1993, 68:1080–1087.
5. Sziray N, Leveleki C, Levay G, Marko B, Harsing LG Jr, Mikics E, Barsy B, Haller
J: Mechanisms underlying the long-term behavioural effects of traumatic
experience in rats: the role of serotonin/noradrenaline balance and
NMDA receptors. Brain Res Bull 2007, 71:376–385.
6. Neuhaus E, Beauchaine TP, Bernier R: Neurobiological correlates of social
functioning in autism. Clin Psychol Rev 2010, 30:733–748.
7. El-Ansary AK, Ben BA, Kotb M: Etiology of autistic features: the persisting
neurotoxic effects of propionic acid. J Neuroinflammation 2012, 9:74.
8. Bonnet U, Bingmann D, Wiemann M: Intracellular pH modulates
spontaneous and epileptiform bioelectric activity of hippocampal
CA3-neurones. Eur Neuropsychopharmacol 2000, 10:97–103.
9. Severson CA, Wang W, Pieribone VA, Dohle CI, Richerson GB: Midbrain
serotonergic neurons are central pH chemoreceptors. Nat Neurosci 2003,
6:1139–1140.
10. Moore H, Grace AA: A role for electrotonic coupling in thestriatum in the
expression of dopamine receptor-mediated stereotypies.
Neuropsychopharmacology 2002, 27:980–992.
11. MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boond
F, Taylor AR, Kavaliers M, Ossenkopp KP: Neurobiological effects of
intraventricular propionic acid in rats: possible role of short chain fatty
acids on the pathogenesis and characteristics of autism spectrum
disorders. Behav Brain Res 2007, 176:149–169.
12. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA,
Frazier TW, Tirouvanziam R: A randomized controlled pilot trial of oral
N-acetylcysteine in children with autism. Biol Psychiatry 2012, 71(11):956–961.
13. Rigo FK, Pasquetti L, Malfatti CR, Fighera MR, Coelho RC, Petri CZ, Mello CF:
Propionic acid induces convulsions and protein carbonylation in rats.
Neurosci Lett 2006, 408:151–154.
14. Gogolla N, Leblanc JJ, Quast KB, Sudhof T, Fagiolini M, Hensch TK: Common
circuit defect of excitatory-inhibitory balance in mouse models of
autism. J Neurodev Disord 2009, 1:172–181.
15. Monks TJ, Ghersi-Egea JF, Philbert M, Cooper AJ, Lock EA: Symposium
overview: the role of glutathione in neuroprotection and neurotoxicity.
Toxicol Sci 1999, 51:161–177.
16. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA:
Metabolic biomarkers of increased oxidative stress and impaired
methylation capacity in children with autism. Am J Clin Nutr 2004,
80:1611–1617.
17. Li N, Wand M, Oberley TD, Sempf JM, Nel AE: Comparisons of the pro-oxidant
and proinflammatory effects of organic diesel exhaust particle chemicals in
bronchial epithelial cells and macrophages. J Immunol 2002, 169:4531–4541.
18. Fahey RC: Glutathione analogs in prokaryotes. Biochim Biophys Acta 2012,
2012:2012. doi:10.1016/j.bbagen.2012.10.006 [Epub ahead of print].
19. Bellomo G, Offhenius S: Altered thiol and calcium homeostasis in
oxidative hepatocellular injury. Hepatology 1985, 5:876–882.
20. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L: Metabolic biomarkers
related to oxidative stress and antioxidant status in Saudi autistic
children. Clin Biochem 2009, 42:1032–1040.
21. Rossignol DA, Frye RE: A review of research trends in physiological
abnormalities in autism spectrum disorders: immune dysregulation,
inflammation, oxidative stress, mitochondrial dysfunction and
environmental toxicant exposures. Mol Psychiatry 2012, 17:389–401.
22. Al-Yafee YA, Al- Ayadhi LY, Haq SH, El-Ansary AK: Novel metabolic
biomarkers related to sulfur-dependent detoxification pathways in
autistic patients of Saudi Arabia. BMC Neurol 2011, 11:139.
23. Hrycaj P, Stratz T, Mennet P, Muller W: Pathogenetic aspects of responsiveness
to ordansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients
with primary fibromyalgia syndrome - a preliminary study. J Rheumatol 1996,
23:1418–1423.
24. Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei
M, Mao H, Byrd JC, Perrotti D, Caligiuri MA: TGF-β utilizes SMAD3 to inhibit
CD16-mediated IFNγ production and antibody-dependent cellular
cytotoxicity in human NK cells. J Immunol 2008, 181(6):3784–3792.
25. Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for
quantification of low levels of DNA damage in individual cells. Exp Cell
Res 1988, 175:184–191.
26. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, Cutler P,
Bock K, Boris M, Bradstreet JJ, Baker SM, Gaylor DW: Metabolic end phenotype
and related genotypes are associated with oxidative stress in children with
autism. Am J Med Genet B Neuropsychiatr Genet 2006, B(8):947.
27. Zachwieja J, Zaniew M, Bobkowski W, Stefaniak E, Warzywoda A, Ostalska-
Nowicka D, Dobrowolska-Zachwieja A, Lewandowska-Stachowiak M,
Siwińska A: Beneficial in vitro effect of N-acetyl-cysteine on oxidative
stress and apoptosis. Pediatr Nephrol 2005, 20:725–731.
28. Farshid AA, Tamaddonfard E, Yahyaee F: Effects of histidine and
N-acetylcysteine on diclofenac-induced anti-inflammatory response in
acute inflammation in rats. Indian J Exp Biol 2010, 48(11):1136–1142.
29. Cui A, Ye Q, Sarria R, Nakamura S, Guzman J, Costabel U: N-acetylcysteine
inhibits TNF-α, TNFR, and TGF-B 1 release by alveolar macrophages in
Aldbass et al. Journal of Neuroinflammation 2013, 10:42 Page 8 of 9
http://www.jneuroinflammation.com/content/10/1/42
idiopathic pulmonary fibrosis in vitro. Sarcoidosis Vasc Diffuse Lung Dis
2009, 26:147–154.
30. Lante F, Meunier J, Guiramand J, De Jesus Ferreira MC, Cambonie G, Aimar
R, Cohen-Solal C, Maurice T, Vignes M, Barbanel G: Late N-acetylcysteine
treatment prevents the deficits induced in the offspring of dams
exposed to an immune stress during gestation. Hippocampus 2008,
18(6):602–609.
31. Paintlia MK, Paintlia AS, Khan M, Singh I, Singh AK: Modulation of
peroxisome proliferator-activated receptor-alpha activity by N-acetyl
cysteine attenuates inhibition of oligodendrocyte development in
lipo-polysaccharide stimulated mixed glial cultures. J Neurochem 2008,
105:956–970.
32. Giovanni S, Sergio D, Filippo D, Antonino D, Giovannangelo O: Antioxidants
as antidepressants: fact or fiction? CNS Drugs 2012, 26(6):477–490.
33. Janaky R, Dohovics R, Saransaari P, Oja SS: Modulation of [3H]dopamine
release by glutathione in mouse striatal slices. Neurochem Res 2007,
32:1357–1364.
34. Himi T, Ikeda M, Yasuhara T, Murota SI: Oxidative neuronal death caused
by glutamate uptake inhibition in cultured hippocampal neurons.
J Neurosci Res 2003, 71:679–688.
35. Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW: The origin and neuronal
function of in vivo nonsynaptic glutamate. J Neurosci 2002, 22:9134–9141.
36. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK: Cystine/
glutamate exchange regulates metabotropic glutamate receptor
presynaptic inhibition of excitatory transmission and vulnerability to
cocaine seeking. J Neurosci 2005, 25:6389–6393.
37. Ogita K, Kitago T, Nakamuta H, Fukuda Y, Koida M, Ogawa Y, Yoneda Y:
Glutathione-induced inhibition of Na + independent and -dependent
bindings of L-[3H]glutamate in rat brain. Life Sci 1986, 39:2411–2418.
38. Varga V, Jenei Z, Janaky R, Saransaari P, Oja SS: Glutathione is an
endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and
2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors.
Neurochem Res 1997, 22:1165–1171.
39. Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT,
Sanacora G, Krystal JH, Coric V: N-acetylcysteine augmentation in
serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Psychopharmacology (Berl) 2006, 184:254–256.
40. Reliene R, Pollard JM, Sobol Z, Trouiller B, Gatti RA, Schiestl RH: N-acetyl
cysteine protects against ionizing radiation-induced DNA damage but
not against cell killing in yeast and mammals. Mutat Res 2009,
665(1–2):37–43.
41. Yang Q, Hergenhahn M, Weninger A, Bartsch H: Cigarette smoke induces
direct DNA damage in the human B-lymphoid cell line Raji.
Carcinogenesis 1999, 20:1769–1775.
42. Yedjou CG, Tchounwou PB: N-acetyl-l-cysteine affords protection against
lead-induced cytotoxicity and oxidative stress in human liver carcinoma
(HepG2) cells. Int J Environ Res Public Health 2007, 4(2):132–137.
43. MacFabe DF: Short-chain fatty acid fermentation products of the gut
microbiome: implications in autism spectrum disorders. Microb Ecol Heal
Dis 2012, 23:19260.
doi:10.1186/1742-2094-10-42
Cite this article as: Aldbass et al.: Protective and therapeutic potency of
N-acetyl-cysteine on propionic acid-induced biochemical autistic
features in rats. Journal of Neuroinflammation 2013 10:42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Aldbass et al. Journal of Neuroinflammation 2013, 10:42 Page 9 of 9
http://www.jneuroinflammation.com/content/10/1/42
